- |||||||||| Leukeran (chlorambucil) / GSK, Gazyva (obinutuzumab) / Roche, Biogen, Imbruvica (ibrutinib) / AbbVie, J&J
Trial primary completion date, Combination therapy: iLLUMINATE : A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment na (clinicaltrials.gov) - Feb 4, 2019 P3, N=212, Active, not recruiting, Results suggest that metronomic chlorambucil in dogs does not achieve plasma concentrations high enough to cause direct cytotoxic or growth inhibitory effects on either glioma or endothelial cells. Trial primary completion date: Oct 2017 --> Mar 2018
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma, Gazyva (obinutuzumab) / Roche, Biogen
Enrollment closed, Enrollment change: A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities (clinicaltrials.gov) - Jul 6, 2018 P1, N=38, Active, not recruiting, Active, not recruiting --> Completed | Trial completion date: Jun 2022 --> May 2018 Recruiting --> Active, not recruiting | N=60 --> 38
- |||||||||| Leukeran (chlorambucil) / GSK, Rituxan (rituximab) / Roche
Enrollment closed, Trial primary completion date: Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL Patients (clinicaltrials.gov) - Oct 12, 2017 P=N/A, N=100, Active, not recruiting, Recruiting --> Active, not recruiting | N=450 --> 600 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2017 --> Dec 2017
- |||||||||| Venclexta (venetoclax) / Roche, AbbVie, Gazyva (obinutuzumab) / Roche, Biogen
Enrollment closed: CLL14: Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Sep 2, 2016 P3, N=445, Active, not recruiting, Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||||||||| Leukeran (chlorambucil) / GSK, Rituxan Hycela (rituximab/hyaluronidase) / Biogen, Roche, Halozyme
Enrollment closed, Trial primary completion date, Combination therapy: Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma (clinicaltrials.gov) - Jul 28, 2016 P2, N=112, Active, not recruiting, Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2017 --> Mar 2016
- |||||||||| Ukoniq (umbralisib) / TG Therap
Enrollment closed, Combination therapy: TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Oct 8, 2015 P1, N=30, Active, not recruiting, Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
|